日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Europe

UK approves Novavax's jab for novel coronavirus

By ANGUS McNEICE in London | China Daily Global | Updated: 2022-02-08 10:04
Share
Share - WeChat
A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. [Photo/Agencies]

The United Kingdom drug regulator has approved a COVID-19 vaccine from United States pharmaceutical company Novavax, becoming the fifth jab to get the green light in the UK, and the first protein-based shot to enter the market.

The UK Medicines and Healthcare products Regulatory Agency, or MHRA, granted regulatory approval for use in adults aged 18 and above, after the jab, which is called Nuvaxovid, was deemed safe and conferred 89.7 percent protection against infection in a phase-3 trial of 15,000 participants in Britain.

That study, which was published in the New England Journal of Medicine, followed on from a separate late-stage trial of 30,000 participants in the US and Mexico, which achieved 90.4 percent efficacy overall.

The UK has already ordered 60 million doses of the vaccine, which is administered in a two-dose regimen, 21 days apart.

"It is great to see our world-renowned medicines regulator approve another COVID-19 vaccine," said UK Health Secretary Sajid Javid. "The next step will be for the independent Joint Committee on Vaccination and Immunisation to consider its use as part of the UK COVID-19 vaccination program."

Nuvaxovid has gained approval in several countries over the last few months including South Africa, India, South Korea and Australia, and Novavax has submitted the treatment for approval to US regulators.

The company is poised to emerge as one of the largest distributors of COVID-19 vaccines in 2022, with plans to manufacture 2.44 billion doses. This would place it in the top five manufacturers this year, along with Pfizer (4.1 billion), Sinovac (1.88 billion), Sinopharm (1.85 billion) and AstraZeneca (1.75 billion), according to projections provided to China Daily by science consultancy Airfinity.

Novavax was bookmarked last year as one of the most promising COVID-19 treatments, following encouraging results in early trials. The jab has a long shelf life of nine months, and does not require ultracold storage. This makes the treatment ideal for distribution in the developing world, and the COVAX vaccine equity project reserved 350 million shots in May 2021.

However, development of the jab has been significantly delayed. Novavax is a relatively small company, and a number of supply and manufacturing issues pushed distribution back to 2022.

The shot from Novavax is the first protein-based COVID-19 vaccine to gain approval in the UK, and experts say that having different varieties of jabs is key to maintaining robust protection in populations against the novel coronavirus. Already in use in treatments for other diseases including Hepatitis B, the technology involves injecting a protein into the body that encourages an immune response, rather than introducing genetic material, as is the case in mRNA vaccines, or using inactivated virus, as seen in several currently available COVID-19 jabs.

June Raine, MHRA chief executive, said the approval followed a "rigorous review of the safety, quality and effectiveness of this vaccine".

Novavax said that serious side effects to the vaccine were low in clinical trials, and the most commonly-reported reactions included headache, nausea or vomiting, muscle pain, joint stiffness, injection site tenderness and fatigue.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 一区二区三区不卡在线观看 | 精品一二三区 | 国产日韩在线看 | 日韩av高清 | 成人深夜免费视频 | 污片在线免费观看 | 欧美区日韩区 | 国产一级片视频 | 日韩视频中文字幕 | 国产精品久久久久久久久久久久久久久久 | 久久久久久国产精品视频 | 日韩第九页 | 成人国产精品一区二区 | 天天色视频 | 在线看片中文字幕 | 日韩免费一区二区 | 精品美女一区二区三区 | 狠狠搞狠狠干 | 久久手机视频 | 国产精品伊人 | 国产天堂第一区 | 亚洲精品播放 | 国产专区精品 | 性色av一区二区三区在线观看 | 五月婷婷色 | 久久精品视频中文字幕 | 中文av免费观看 | 国产日日日 | 欧美一a一片一级一片 | 成人观看 | 污视频在线免费观看 | 色视频在线观看 | 夜夜操影院 | 亚洲理论在线 | 中文天堂在线播放 | 少妇高潮av久久久久久 | 99热这里 | 91在线一区二区 | 日本一级一片免费视频 | 国产亚洲精品久久久久久 | 国产精选第一页 |